The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

Novo Nordisk NVO announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction in the long term. NVO expects to ...

The FDA approved a higher 7.2 mg dose of injectable semaglutide for adults with overweight and obesity, Novo Nordisk announced. Once-weekly injectable semaglutide 7.2 mg (Wegovy HD, Novo Nordisk) ...

The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest expansion in a rapidly growing market for weight-loss treatments. The newly ...

Federal regulators have approved a new, higher-dose version of the obesity drug Wegovy that may help users lose more weight and keep it off. The U.S. Food and Drug Administration approved a ...

Gastrointestinal tolerability remained the dominant adverse-reaction cluster, aligning with established GLP‑1 receptor agonist class effects across dose ranges. A higher-dose signal of altered skin ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg.

By Sneha S K and Sahil Pandey March 20 (Reuters) - The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’ therapy for a rare form of obesity caused by brain damage, making ...